JP2005506293A - サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法 - Google Patents

サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法 Download PDF

Info

Publication number
JP2005506293A
JP2005506293A JP2002572907A JP2002572907A JP2005506293A JP 2005506293 A JP2005506293 A JP 2005506293A JP 2002572907 A JP2002572907 A JP 2002572907A JP 2002572907 A JP2002572907 A JP 2002572907A JP 2005506293 A JP2005506293 A JP 2005506293A
Authority
JP
Japan
Prior art keywords
ocular degeneration
composition
thymosin
dry eye
degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002572907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506293A5 (enExample
Inventor
ゴールドスタイン，アラン・エル
Original Assignee
リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド filed Critical リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド
Publication of JP2005506293A publication Critical patent/JP2005506293A/ja
Publication of JP2005506293A5 publication Critical patent/JP2005506293A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2002572907A 2001-03-15 2002-03-14 サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法 Pending JP2005506293A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27564501P 2001-03-15 2001-03-15
PCT/US2002/007730 WO2002074193A2 (en) 2001-03-15 2002-03-14 METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN ss4 (Tss4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009120011A Division JP2009179638A (ja) 2001-03-15 2009-05-18 サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を含む組成物の使用

Publications (2)

Publication Number Publication Date
JP2005506293A true JP2005506293A (ja) 2005-03-03
JP2005506293A5 JP2005506293A5 (enExample) 2005-12-22

Family

ID=23053251

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002572907A Pending JP2005506293A (ja) 2001-03-15 2002-03-14 サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
JP2009120011A Withdrawn JP2009179638A (ja) 2001-03-15 2009-05-18 サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を含む組成物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009120011A Withdrawn JP2009179638A (ja) 2001-03-15 2009-05-18 サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を含む組成物の使用

Country Status (8)

Country Link
US (1) US20040131626A1 (enExample)
EP (1) EP1383529A4 (enExample)
JP (2) JP2005506293A (enExample)
CN (2) CN101195025A (enExample)
AU (2) AU2002255736B2 (enExample)
CA (1) CA2441147A1 (enExample)
MX (1) MXPA03008359A (enExample)
WO (1) WO2002074193A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543878A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
JP2020530435A (ja) * 2017-06-14 2020-10-22 ヒューオンス カンパニー, リミテッドHuons Co., Ltd. Ｇｌｙ−Ｔβ４（Ｇｌｙ−チモシンβ４）を含有する眼球乾燥症の治療用薬学的組成物
JP2021504349A (ja) * 2017-11-24 2021-02-15 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531318B2 (en) * 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
WO2006076255A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing microbial eye infection
CN100372572C (zh) * 2005-09-29 2008-03-05 北京诺思兰德生物技术有限责任公司 携带人胸腺素β4基因的重组质粒
US20080132451A1 (en) * 2006-12-01 2008-06-05 Alcon Manufacturing Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
CN102924573B (zh) * 2012-11-13 2014-07-23 兆科药业（广州）有限公司 一种肌动蛋白结合肽及其用途
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
CN113599371A (zh) * 2021-09-06 2021-11-05 郑州大学 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
AT401180B (de) * 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
JP3128203B2 (ja) * 1997-02-10 2001-01-29 一男 坪田 分泌腺細胞とリンパ球との接着阻害剤
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
PT1100529E (pt) * 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543878A (ja) * 2005-06-17 2008-12-04 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 凍結乾燥したかまたは凍結乾燥させることができる形態であるｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔペプチド組成物
US8383576B2 (en) 2005-06-17 2013-02-26 Regenerx Biopharmaceuticals, Inc. LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
US9585941B2 (en) 2005-06-17 2017-03-07 Regenerx Biopharmaceuticals, Inc. Eye drop formulation
US9821030B2 (en) 2005-06-17 2017-11-21 Regenerx Biopharmaceuticals, Inc. LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
US10004785B2 (en) 2005-06-17 2018-06-26 Regenerx Biopharmaceuticals, Inc. LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
JP2020530435A (ja) * 2017-06-14 2020-10-22 ヒューオンス カンパニー, リミテッドHuons Co., Ltd. Ｇｌｙ−Ｔβ４（Ｇｌｙ−チモシンβ４）を含有する眼球乾燥症の治療用薬学的組成物
JP2021504349A (ja) * 2017-11-24 2021-02-15 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物

Also Published As

Publication number Publication date
CA2441147A1 (en) 2002-09-26
CN101195025A (zh) 2008-06-11
WO2002074193A2 (en) 2002-09-26
AU2002255736B2 (en) 2006-08-31
MXPA03008359A (es) 2004-10-15
CN100360174C (zh) 2008-01-09
US20040131626A1 (en) 2004-07-08
EP1383529A2 (en) 2004-01-28
WO2002074193A3 (en) 2003-12-04
AU2008261127A1 (en) 2009-01-15
CN1638789A (zh) 2005-07-13
EP1383529A4 (en) 2005-06-29
HK1074577A1 (en) 2005-11-18
JP2009179638A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
JP2009179638A (ja) サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を含む組成物の使用
AU2002336408B2 (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
AU2002255736A1 (en) Methods of Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
US20110020449A1 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US20080096817A1 (en) METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
AU2004308378B2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
JP2007521336A5 (enExample)
AU2002309842B2 (en) Treating epidermlyosis bullosa with thymosin beta 4
AU2006233251B2 (en) Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
HK1118017A (en) THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
US20040170625A1 (en) Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
MXPA06006849A (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
WO2006076254A2 (en) Method of treating or preventing respiratory microbial infection of respiratory tissue

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090427